{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T01:49:20Z","timestamp":1793411360935,"version":"4.5.0"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:00:00Z","timestamp":1763942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:00:00Z","timestamp":1763942400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Molecular profiling has significantly advanced neuro-oncology, enabling the integration of biomarkers into the diagnosis and management of brain tumors. Precision medicine is emerging as a promising strategy; however, the marked heterogeneity of central nervous system tumors results in a low prevalence of actionable targets, limiting clinical applicability. Despite these challenges, ongoing progress in genetics and molecular biology offers new opportunities for targeted therapies. The incidence and clinical relevance of biomarkers vary across tumor types and age groups, reflecting the biological complexity of brain neoplasms throughout life.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A multidisciplinary expert panel conducted a systematic review of the literature and developed a consensus statement addressing key predictive biomarkers across pediatric, adolescent and young adult (AYA), adult, and elderly populations. Evidence was evaluated for diagnostic, prognostic, and therapeutic relevance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Clinical benefit from targeted therapies has been demonstrated for a limited number of alterations, including\n                      <jats:bold>BRAF p.V600E<\/jats:bold>\n                      ,\n                      <jats:bold>NTRK fusions<\/jats:bold>\n                      ,\n                      <jats:bold>EGFR<\/jats:bold>\n                      ,\n                      <jats:bold>H3 K27M<\/jats:bold>\n                      , and\n                      <jats:bold>IDH1\/2 mutations<\/jats:bold>\n                      , while several additional biomarkers remain under investigation. The consensus provides an age-stratified overview of these molecular alterations and discusses challenges such as variability in testing approaches, interpretation of variants of uncertain significance, and limited access to comprehensive molecular diagnostics.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Based on current evidence and expert opinion, the statement highlights the need for age-adapted testing strategies, multidisciplinary molecular tumor boards, and increased clinical trial availability for patients with rare or emerging biomarkers. These recommendations aim to support the implementation of precision medicine and improve outcomes across all age groups.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11060-025-05329-x","type":"journal-article","created":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T13:12:13Z","timestamp":1763989933000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Diagnostic and predictive molecular biomarkers in brain tumors across the lifespan: an age-stratified consensus statement"],"prefix":"10.1007","volume":"176","author":[{"given":"Angela","family":"Mastronuzzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Franceschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"D\u2019Antonio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Bennicelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Berzero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenia","family":"Cella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Filippi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaetano","family":"Lanzetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Marchioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Milanaccio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Simonelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Bini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Silvani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Pace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,24]]},"reference":[{"issue":"2","key":"5329_CR1","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1093\/neuonc\/noae213","volume":"27","author":"MJ n Den Bent","year":"2025","unstructured":"Van Den Bent MJ, Franceschi E, Touat M, French PJ, Idbaih A, Lombardi G et al (2025) Updated EANO guideline on rational molecular testing of gliomas, glioneuronal, and neuronal tumors in adults for targeted therapy selection\u2014Update 1. Neuro-Oncol 27(2):331\u2013337","journal-title":"Neuro-Oncol"},{"issue":"8","key":"5329_CR2","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","volume":"23","author":"DN Louis","year":"2021","unstructured":"Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D et al (2021) The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro-Oncol 23(8):1231\u20131251","journal-title":"Neuro-Oncol"},{"key":"5329_CR3","doi-asserted-by":"crossref","unstructured":"Haynes HR, Camelo-Piragua S, Kurian KM. Prognostic and predictive biomarkers in adult and pediatric gliomas: toward personalized treatment. Front Oncol [Internet]. 2014 Mar 24 [cited 2025 Jun 10];4. Available from: http:\/\/journal.frontiersin.org\/article\/10.3389\/fonc.2014.00047\/abstract","DOI":"10.3389\/fonc.2014.00047"},{"issue":"10","key":"5329_CR4","doi-asserted-by":"publisher","first-page":"3329","DOI":"10.1007\/s00381-024-06449-x","volume":"40","author":"J Bennett","year":"2024","unstructured":"Bennett J, Yeo KK, Tabori U, Hawkins C, Lim-Fat MJ (2024) Pediatric-type low-grade gliomas in adolescents and young adults\u2014challenges and emerging paradigms. Childs Nerv Syst 40(10):3329\u20133339","journal-title":"Childs Nerv Syst"},{"issue":"3","key":"5329_CR5","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/s41571-020-00447-z","volume":"18","author":"M Van Den Weller","year":"2021","unstructured":"Van Den Weller M, Preusser M, Le Rhun E, Tonn JC, Minniti G et al (2021) EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat Rev Clin Oncol 18(3):170\u2013186","journal-title":"Nat Rev Clin Oncol"},{"issue":"17","key":"5329_CR6","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.3390\/cells13171492","volume":"13","author":"A Yoel","year":"2024","unstructured":"Yoel A, Adjumain S, Liang Y, Daniel P, Firestein R, Tsui V (2024) Emerging and biological concepts in pediatric High-Grade gliomas. Cells 13(17):1492","journal-title":"Cells"},{"issue":"1","key":"5329_CR7","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1093\/neuonc\/noae186","volume":"27","author":"MJ Lim-Fat","year":"2025","unstructured":"Lim-Fat MJ, Bennett J, Ostrom Q, Touat M, Franceschi E, Schulte J et al (2025) Central nervous system tumors in adolescents and young adults: A society for Neuro-Oncology consensus review on diagnosis, management, and future directions. Neuro-Oncol 27(1):13\u201332","journal-title":"Neuro-Oncol"},{"issue":"12","key":"5329_CR8","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.3390\/brainsci11121655","volume":"11","author":"A Erira","year":"2021","unstructured":"Erira A, Velandia F, Penagos J, Zubieta C, Arboleda G (2021) Differential regulation of the EGFR\/PI3K\/AKT\/PTEN pathway between Low- and High-Grade gliomas. Brain Sci 11(12):1655","journal-title":"Brain Sci"},{"issue":"5","key":"5329_CR9","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1093\/neuonc\/noad008","volume":"25","author":"D Capper","year":"2023","unstructured":"Capper D, Reifenberger G, French PJ, Schweizer L, Weller M, Touat M et al (2023) EANO guideline on rational molecular testing of gliomas, glioneuronal, and neuronal tumors in adults for targeted therapy selection. Neuro-Oncol 25(5):813\u2013826","journal-title":"Neuro-Oncol"},{"issue":"18suppl","key":"5329_CR10","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.1200\/jco.2007.25.18_suppl.2084","volume":"25","author":"M Preusser","year":"2007","unstructured":"Preusser M, Hassler M, Elandt K, Gelpi E, Hainfellner J, Baur M et al (2007) Analysis of MGMT promoter methylation status in high grade glioma patients with long term and conventional survival times: A retrospective study. J Clin Oncol 25(18suppl):2084\u20132084","journal-title":"J Clin Oncol"},{"issue":"7","key":"5329_CR11","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1056\/NEJMoa2304194","volume":"389","author":"IK Van Den Mellinghoff","year":"2023","unstructured":"Van Den Mellinghoff IK, Blumenthal DT, Touat M, Peters KB, Clarke J et al (2023) Vorasidenib in IDH1- or IDH2-Mutant Low-Grade glioma. N Engl J Med 389(7):589\u2013601","journal-title":"N Engl J Med"},{"key":"5329_CR12","doi-asserted-by":"crossref","unstructured":"Horowitz K, Fotopoulos NH, Mistry AJ, Simo J, Medeiros M, Bucco ID et al. Enhancing Variant of Uncertain Significance (VUS) Interpretation in Neurogenetics: Collaborative Experiences from a Tertiary Care Centre [Internet]. 2024 [cited 2025 May 29]. Available from: http:\/\/medrxiv.org\/lookup\/doi\/10.1101\/2024.05.13.24307186","DOI":"10.1101\/2024.05.13.24307186"},{"issue":"6","key":"5329_CR13","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1097\/WCO.0000000000001319","volume":"37","author":"D Demaliaj","year":"2024","unstructured":"Demaliaj D, Gardner SL (2024) Novel therapies for pediatric low grade glioma. Curr Opin Neurol 37(6):702\u2013707","journal-title":"Curr Opin Neurol"},{"issue":"4","key":"5329_CR14","doi-asserted-by":"publisher","first-page":"551","DOI":"10.18632\/oncotarget.26560","volume":"10","author":"SA Toll","year":"2019","unstructured":"Toll SA, Tran HN, Cotter J, Judkins AR, Tamrazi B, Biegel JA et al (2019) Sustained response of three pediatric BRAFV600E mutated high-grade gliomas to combined BRAF and MEK inhibitor therapy. Oncotarget 10(4):551\u2013557","journal-title":"Oncotarget"},{"issue":"1","key":"5329_CR15","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/s41591-023-02668-y","volume":"30","author":"LB Kilburn","year":"2024","unstructured":"Kilburn LB, Khuong-Quang DA, Hansford JR, Van Der Landi D, Leary SES et al (2024) The type II RAF inhibitor Tovorafenib in relapsed\/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial. Nat Med 30(1):207\u2013217","journal-title":"Nat Med"},{"issue":"8","key":"5329_CR16","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1158\/1078-0432.CCR-24-3439","volume":"31","author":"S Singh","year":"2025","unstructured":"Singh S, Bradford D, Chatterjee S, Li X, Aungst SL, Skinner AM et al (2025) FDA approval summary: Tovorafenib for relapsed or refractory BRAF-Altered pediatric Low-Grade glioma. Clin Cancer Res 31(8):1383\u20131389","journal-title":"Clin Cancer Res"},{"key":"5329_CR17","unstructured":"https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-tovorafenib-patients-relapsed-or-refractory-braf-altered-pediatric"},{"key":"5329_CR18","doi-asserted-by":"publisher","first-page":"1515538","DOI":"10.3389\/fonc.2024.1515538","volume":"14","author":"L Evans","year":"2025","unstructured":"Evans L, Trinder S, Dodgshun A, Eisenstat DD, Whittle JR, Hansford JR et al (2025) IDH-mutant gliomas in children and adolescents - from biology to clinical trials. Front Oncol 14:1515538","journal-title":"Front Oncol"},{"issue":"9","key":"5329_CR19","doi-asserted-by":"publisher","first-page":"648","DOI":"10.3390\/diagnostics10090648","volume":"10","author":"G Ceglie","year":"2020","unstructured":"Ceglie G, Vinci M, Carai A, Rossi S, Colafati GS, Cacchione A et al (2020) Infantile\/Congenital High-Grade gliomas: molecular features and therapeutic perspectives. Diagnostics 10(9):648","journal-title":"Diagnostics"},{"issue":"3","key":"5329_CR20","doi-asserted-by":"publisher","first-page":"753","DOI":"10.3390\/ijms21030753","volume":"21","author":"A Gambella","year":"2020","unstructured":"Gambella A, Senetta R, Collemi G, Vallero SG, Monticelli M, Cofano F et al (2020) NTRK fusions in central nervous system tumors: A Rare, but worthy target. Int J Mol Sci 21(3):753","journal-title":"Int J Mol Sci"},{"issue":"6","key":"5329_CR21","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1093\/neuonc\/noab274","volume":"24","author":"F Doz","year":"2022","unstructured":"Doz F, Van Tilburg CM, Geoerger B, H\u00f8jgaard M, \u00d8ra I, Boni V et al (2022) Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors. Neuro-Oncol 24(6):997\u20131007","journal-title":"Neuro-Oncol"},{"key":"5329_CR22","unstructured":"Lamoureux AA, Fisher MJ, Lemelle L, Pfaff E, Amir-Yazdani P, Kramm C et al (2024) Clinical characteristics and outcomes of central nervous system tumors harboring NTRK gene fusions. Clin Cancer Res. OF1\u201312"},{"issue":"3","key":"5329_CR23","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1158\/1078-0432.CCR-24-0581","volume":"31","author":"AA Lamoureux","year":"2025","unstructured":"Lamoureux AA, Fisher MJ, Lemelle L, Pfaff E, Amir-Yazdani P, Kramm C et al (2025) Clinical characteristics and outcomes of central nervous system tumors harboring NTRK gene fusions. Clin Cancer Res 31(3):561\u2013572","journal-title":"Clin Cancer Res"},{"issue":"13","key":"5329_CR24","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1200\/JCO.23.01134","volume":"42","author":"I Arrillaga-Romany","year":"2024","unstructured":"Arrillaga-Romany I, Gardner SL, Odia Y, Aguilera D, Allen JE, Batchelor T et al (2024) ONC201 (Dordaviprone) in recurrent H3 K27M\u2013Mutant diffuse midline glioma. J Clin Oncol 42(13):1542\u20131552","journal-title":"J Clin Oncol"},{"key":"5329_CR25","unstructured":"Christian EA, Rutka JT (2025) Emerging frontiers in DIPG treatment: A new hope. Neuro-Oncol. noaf117"},{"key":"5329_CR26","unstructured":"https:\/\/www.targetedonc.com\/view\/behind-the-fda-approval-of-dordaviprone-a-new-hope-for-glioma"},{"issue":"1","key":"5329_CR27","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1186\/s40478-024-01889-7","volume":"12","author":"D Noack","year":"2024","unstructured":"Noack D, Wach J, Barrantes-Freer A, Nicolay NH, G\u00fcresir E, Seidel C (2024) Homozygous CDKN2A\/B deletions in low- and high-grade glioma: a meta-analysis of individual patient data and predictive values of p16 immunohistochemistry testing. Acta Neuropathol Commun 12(1):180","journal-title":"Acta Neuropathol Commun"},{"issue":"24","key":"5329_CR28","doi-asserted-by":"publisher","first-page":"16619","DOI":"10.18632\/oncotarget.24618","volume":"9","author":"NK Chaturvedi","year":"2018","unstructured":"Chaturvedi NK, Kling MJ, Coulter DW, McGuire TR, Ray S, Kesherwani V et al (2018) Improved therapy for medulloblastoma: targeting Hedgehog and PI3K-mTOR signaling pathways in combination with chemotherapy. Oncotarget 9(24):16619\u201316633","journal-title":"Oncotarget"},{"key":"5329_CR29","doi-asserted-by":"crossref","unstructured":"Kian W, Roisman LC, Goldstein IM, Abo-Quider A, Samueli B, Wallach N et al (2020) Vismodegib as first-line treatment of mutated sonic hedgehog pathway in adult medulloblastoma. JCO Precis Oncol. (4):437\u2013441","DOI":"10.1200\/PO.19.00264"},{"issue":"3","key":"5329_CR30","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1227\/neu.0000000000002923","volume":"95","author":"B Wang","year":"2024","unstructured":"Wang B, Yan M, Han B, Liu X, Liu P (2024) Impact of molecular subgroups on prognosis and survival outcomes in posterior fossa ependymomas: A retrospective study of 412 cases. Neurosurgery 95(3):651\u2013659","journal-title":"Neurosurgery"},{"issue":"1","key":"5329_CR31","doi-asserted-by":"publisher","first-page":"vdac056","DOI":"10.1093\/noajnl\/vdac056","volume":"4","author":"JR Hansford","year":"2022","unstructured":"Hansford JR, Huang J, Endersby R, Dodgshun AJ, Li BK, Hwang E et al (2022) Pediatric pineoblastoma: A pooled outcome study of North American and Australian therapeutic data. Neuro-Oncol Adv 4(1):vdac056","journal-title":"Neuro-Oncol Adv"},{"issue":"8","key":"5329_CR32","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1056\/NEJMoa1502309","volume":"373","author":"DM Hyman","year":"2015","unstructured":"Hyman DM, Puzanov I, Subbiah V, Faris JE, Chau I, Blay JY et al (2015) Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N Engl J Med 373(8):726\u2013736","journal-title":"N Engl J Med"},{"key":"5329_CR33","doi-asserted-by":"publisher","first-page":"1154246","DOI":"10.3389\/fonc.2023.1154246","volume":"13","author":"SM Trinder","year":"2023","unstructured":"Trinder SM, McKay C, Power P, Topp M, Chan B, Valvi S et al (2023) BRAF-mediated brain tumors in adults and children: A review and the Australian and new Zealand experience. Front Oncol 13:1154246","journal-title":"Front Oncol"},{"issue":"12","key":"5329_CR34","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1056\/NEJMoa2303815","volume":"389","author":"E Bouffet","year":"2023","unstructured":"Bouffet E, Hansford JR, Garr\u00e8 ML, Hara J, Plant-Fox A, Aerts I et al (2023) Dabrafenib plus Trametinib in pediatric glioma with BRAF V600 mutations. N Engl J Med 389(12):1108\u20131120","journal-title":"N Engl J Med"},{"issue":"1","key":"5329_CR35","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s13072-025-00616-3","volume":"18","author":"AR De Abreu","year":"2025","unstructured":"De Abreu AR, Ibrahim J, Lemonidis V, Mateiu L, Van Camp G, Op De Beeck K (2025) Comparison of current methods for genome-wide DNA methylation profiling. Epigenetics Chromatin 18(1):57","journal-title":"Epigenetics Chromatin"},{"key":"5329_CR36","doi-asserted-by":"publisher","first-page":"982608","DOI":"10.3389\/fonc.2022.982608","volume":"12","author":"H Takami","year":"2022","unstructured":"Takami H, Ichimura K (2022) Biomarkers for risk-based treatment modifications for CNS germ cell tumors: updates on biological underpinnings, clinical trials, and future directions. Front Oncol 12:982608","journal-title":"Front Oncol"},{"issue":"1","key":"5329_CR37","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1007\/s10014-020-00379-7","volume":"38","author":"G Almuhaisen","year":"2021","unstructured":"Almuhaisen G, Alhalaseh Y, Mansour R, Abu-Shanab A, Al-Ghnimat S, Al-Hussaini M (2021) Frequency of mismatch repair protein deficiency and PD-L1 in high-grade gliomas in adolescents and young adults (AYA). Brain Tumor Pathol 38(1):14\u201322","journal-title":"Brain Tumor Pathol"},{"issue":"1","key":"5329_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/JCO.19.02105","volume":"38","author":"A Marabelle","year":"2020","unstructured":"Marabelle A, Le DT, Ascierto PA, Di Giacomo AM, De Jesus-Acosta A, Delord JP et al (2020) Efficacy of pembrolizumab in patients with noncolorectal high microsatellite Instability\/Mismatch Repair\u2013Deficient cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol 38(1):1\u201310","journal-title":"J Clin Oncol"},{"key":"5329_CR39","unstructured":"A. Puccini1,2 \u2219 F. Grillo3,4 \u2219 M. Fassan5,6 \u2219 S. Lonardi7 \u2219 M. Genuardi8,9 \u2219 R. Cannizzaro10,11 \u2219 G.M. Cavestro12 \u2219 F. Marmorino13,14 \u2219 V. Conca13,14 \u2219 L. Salvatore15,16 \u2219 F. Bergamo7 \u2219 F. Tosi17 \u2219 F. Morano18 \u2219 V. Dapr\u00e02 \u2219 C. Molica19 \u2219 D. Barana20 \u2219 A. Guglielmi21 \u2219 C. Signorelli22 \u2219 M. D\u2019Amico23 \u2219 F. Zoratto24 \u2219 D. Iacono25 \u2219 A. Morabito26 \u2219 G. Martini27 \u2219 A. Fabbroncini28 \u2219 M. Duro29 \u2219 G. Bruera30 \u2219 A. Auriemma31 \u2219 B. Bonanni32 \u2219 A. Percesepe33 \u2219 M. Dono34 \u2219 L. Battistuzzi35 \u2219 R. Labianca36 \u2219 L. Boni37 \u2219 S. Sciallero1 stefania.sciallero@hsanmartino.it and the ItaLynch Working Group. ItaLynch: an ongoing Italian study to evaluate the feasibility of mainstreaming the diagnosis of Lynch syndrome in colorectal cancer patients"},{"issue":"2","key":"5329_CR40","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/s41374-021-00694-3","volume":"102","author":"H Kim","year":"2022","unstructured":"Kim H, Lim KY, Park JW, Kang J, Won JK, Lee K et al (2022) Sporadic and Lynch syndrome-associated mismatch repair-deficient brain tumors. Lab Invest 102(2):160\u2013171","journal-title":"Lab Invest"},{"issue":"15","key":"5329_CR41","doi-asserted-by":"publisher","first-page":"7810","DOI":"10.1158\/0008-5472.CAN-06-1114","volume":"66","author":"H Hampel","year":"2006","unstructured":"Hampel H, Frankel W, Panescu J, Lockman J, Sotamaa K, Fix D et al (2006) Screening for Lynch syndrome (Hereditary nonpolyposis colorectal cancer) among endometrial cancer patients. Cancer Res 66(15):7810\u20137817","journal-title":"Cancer Res"},{"issue":"6349","key":"5329_CR42","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1126\/science.aan6733","volume":"357","author":"DT Le","year":"2017","unstructured":"Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK et al (2017) Mismatch repair deficiency predicts response of solid tumors to PD-1 Blockade. Science 357(6349):409\u2013413","journal-title":"Science"},{"issue":"4","key":"5329_CR43","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1111\/ene.12647","volume":"22","author":"C Therkildsen","year":"2015","unstructured":"Therkildsen C, Ladelund S, Rambech E, Persson A, Petersen A, Nilbert M (2015) Glioblastomas, Astrocytomas and oligodendrogliomas linked to Lynch syndrome. Eur J Neurol 22(4):717\u2013724","journal-title":"Eur J Neurol"},{"issue":"1","key":"5329_CR44","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1007\/s12672-024-01435-w","volume":"15","author":"MS Hosseini","year":"2024","unstructured":"Hosseini MS (2024) Current insights and future directions of Li-Fraumeni syndrome. Discov Oncol 15(1):561","journal-title":"Discov Oncol"},{"issue":"1","key":"5329_CR45","doi-asserted-by":"publisher","first-page":"vdac016","DOI":"10.1093\/noajnl\/vdac016","volume":"4","author":"H Yan","year":"2022","unstructured":"Yan H, Zabih V, Bartels U, Das S, Nathan P, Gupta S (2022) Prognostic factors related to overall survival in adolescent and young adults with medulloblastoma: A systematic review. Neuro-Oncol Adv 4(1):vdac016","journal-title":"Neuro-Oncol Adv"},{"issue":"24","key":"5329_CR46","doi-asserted-by":"publisher","first-page":"2646","DOI":"10.1200\/JCO.2014.60.1591","volume":"33","author":"GW Robinson","year":"2015","unstructured":"Robinson GW, Orr BA, Wu G, Gururangan S, Lin T, Qaddoumi I et al (2015) Vismodegib exerts targeted efficacy against recurrent Sonic Hedgehog\u2013Subgroup medulloblastoma: results from phase II pediatric brain tumor consortium studies PBTC-025B and PBTC-032. J Clin Oncol 33(24):2646\u20132654","journal-title":"J Clin Oncol"},{"key":"5329_CR47","doi-asserted-by":"publisher","first-page":"688108","DOI":"10.3389\/fchem.2021.688108","volume":"9","author":"M Caimano","year":"2021","unstructured":"Caimano M, Lospinoso Severini L, Loricchio E, Infante P, Di Marcotullio L (2021) Drug delivery systems for Hedgehog inhibitors in the treatment of SHH-Medulloblastoma. Front Chem 9:688108","journal-title":"Front Chem"},{"issue":"20","key":"5329_CR48","doi-asserted-by":"publisher","first-page":"7859","DOI":"10.1073\/pnas.1114718109","volume":"109","author":"MJ Lee","year":"2012","unstructured":"Lee MJ, Hatton BA, Villavicencio EH, Khanna PC, Friedman SD, Ditzler S et al (2012) Hedgehog pathway inhibitor saridegib (IPI-926) increases lifespan in a mouse Medulloblastoma model. Proc Natl Acad Sci 109(20):7859\u20137864","journal-title":"Proc Natl Acad Sci"},{"issue":"13","key":"5329_CR49","doi-asserted-by":"publisher","first-page":"3829","DOI":"10.1021\/jm801420y","volume":"52","author":"N Mahindroo","year":"2009","unstructured":"Mahindroo N, Punchihewa C, Fujii N (2009) Hedgehog-Gli signaling pathway inhibitors as anticancer agents. J Med Chem 52(13):3829\u20133845","journal-title":"J Med Chem"},{"issue":"1","key":"5329_CR50","doi-asserted-by":"publisher","first-page":"vdab097","DOI":"10.1093\/noajnl\/vdab097","volume":"3","author":"V Pereira","year":"2021","unstructured":"Pereira V, Torrejon J, Kariyawasam D, Berlanga P, Guerrini-Rousseau L, Ayrault O et al (2021) Clinical and molecular analysis of smoothened inhibitors in Sonic Hedgehog Medulloblastoma. Neuro-Oncol Adv 3(1):vdab097","journal-title":"Neuro-Oncol Adv"},{"issue":"12","key":"5329_CR51","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1097\/PAS.0000000000002118","volume":"47","author":"A Muench","year":"2023","unstructured":"Muench A, Teichmann D, Spille D, Kuzman P, Perez E, May SA et al (2023) A novel type of IDH-wildtype glioma characterized by gliomatosis Cerebri-like growth Pattern, TERT promoter Mutation, and distinct epigenetic profile. Am J Surg Pathol 47(12):1364\u20131375","journal-title":"Am J Surg Pathol"},{"issue":"7","key":"5329_CR52","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1038\/s41582-024-00967-7","volume":"20","author":"R Rud\u00e0","year":"2024","unstructured":"Rud\u00e0 R, Van Den Horbinski C, Preusser M, Soffietti R (2024) IDH Inhibition in gliomas: from preclinical models to clinical trials. Nat Rev Neurol 20(7):395\u2013407","journal-title":"Nat Rev Neurol"},{"issue":"1","key":"5329_CR53","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/s41698-024-00646-2","volume":"8","author":"MD Lin","year":"2024","unstructured":"Lin MD, Tsai ACY, Abdullah KG, McBrayer SK, Shi DD (2024) Treatment of IDH-mutant glioma in the INDIGO era. Npj Precis Oncol 8(1):149","journal-title":"Npj Precis Oncol"},{"issue":"5","key":"5329_CR54","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.3390\/ijms25052529","volume":"25","author":"E Obrador","year":"2024","unstructured":"Obrador E, Moreno-Murciano P, Oriol-Caballo M, L\u00f3pez-Blanch R, Pineda B, Guti\u00e9rrez-Arroyo J et al (2024) Glioblastoma therapy: Past, present and future. Int J Mol Sci 25(5):2529","journal-title":"Int J Mol Sci"},{"issue":"13","key":"5329_CR55","doi-asserted-by":"publisher","first-page":"e23809","DOI":"10.1096\/fj.202400019RR","volume":"38","author":"R Vlashi","year":"2024","unstructured":"Vlashi R, Sun F, Zheng C, Zhang X, Liu J, Chen G (2024) The molecular biology of NF2 \/Merlin on tumorigenesis and development. FASEB J 38(13):e23809","journal-title":"FASEB J"},{"issue":"5","key":"5329_CR56","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1038\/s41591-023-02321-8","volume":"29","author":"V Subbiah","year":"2023","unstructured":"Subbiah V, Kreitman RJ, Wainberg ZA, Gazzah A, Lassen U, Stein A et al (2023) Dabrafenib plus Trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial. Nat Med 29(5):1103\u20131112","journal-title":"Nat Med"},{"issue":"5","key":"5329_CR57","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1002\/lio2.643","volume":"6","author":"DB Welling","year":"2021","unstructured":"Welling DB, Collier KA, Burns SS, Oblinger JL, Shu E, Miles-Markley BA et al (2021) Early phase clinical studies of AR \u201042, a histone deacetylase inhibitor, for neurofibromatosis type 2\u2010associated vestibular schwannomas and meningiomas. Laryngoscope Investig Otolaryngol 6(5):1008\u20131019","journal-title":"Laryngoscope Investig Otolaryngol"},{"issue":"1","key":"5329_CR58","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s11060-019-03337-2","volume":"146","author":"M n Den Bent","year":"2020","unstructured":"n Den Bent M, Azaro A, De Vos F, Sepulveda J, Yung WKA, Wen PY et al (2020) A phase Ib\/II, open-label, multicenter study of INC280 (capmatinib) alone and in combination with buparlisib (BKM120) in adult patients with recurrent glioblastoma. J Neurooncol 146(1):79\u201389","journal-title":"J Neurooncol"},{"issue":"1","key":"5329_CR59","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1186\/s13046-019-1269-x","volume":"38","author":"F Cheng","year":"2019","unstructured":"Cheng F, Guo D (2019) MET in glioma: signaling pathways and targeted therapies. J Exp Clin Cancer Res 38(1):270","journal-title":"J Exp Clin Cancer Res"},{"key":"5329_CR60","doi-asserted-by":"crossref","unstructured":"Lee A, Arasaratnam M, Chan DLH, Khasraw M, Howell VM, Wheeler H (2020) Anti-epidermal growth factor receptor therapy for glioblastoma in adults. Cochrane Database Syst Rev [Internet]. [cited 2025 Jan 9];(5). Available from: https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD013238.pub2\/full","DOI":"10.1002\/14651858.CD013238.pub2"},{"key":"5329_CR61","doi-asserted-by":"crossref","unstructured":"Lee A, Arasaratnam M, Chan DLH, Khasraw M, Howell VM, Wheeler H (2020) Anti-epidermal growth factor receptor therapy for glioblastoma in adults. Cochrane Gynaecological, Neuro-oncology and Orphan Cancer Group, editor. Cochrane Database Syst Rev [Internet]. 2020 May 12 [cited 2025 Jun 20];(8). Available from: https:\/\/doi.wiley.com\/10.1002\/14651858.CD013238.pub2","DOI":"10.1002\/14651858.CD013238.pub2"},{"key":"5329_CR62","first-page":"100761","volume":"46","author":"NK Mazarakis","year":"2024","unstructured":"Mazarakis NK, Robinson SD, Sinha P, Koutsarnakis C, Komaitis S, Stranjalis G et al (2024) Management of glioblastoma in elderly patients: A review of the literature. Clin Transl Radiat Oncol 46:100761","journal-title":"Clin Transl Radiat Oncol"},{"issue":"2","key":"5329_CR63","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1093\/neuonc\/noy132","volume":"21","author":"A Mansouri","year":"2019","unstructured":"Mansouri A, Hachem LD, Mansouri S, Nassiri F, Laperriere NJ, Xia D et al (2019) MGMT promoter methylation status testing to guide therapy for glioblastoma: refining the approach based on emerging evidence and current challenges. Neuro-Oncol 21(2):167\u2013178","journal-title":"Neuro-Oncol"},{"issue":"Supplement2","key":"5329_CR64","doi-asserted-by":"publisher","first-page":"ii33","DOI":"10.1093\/noajnl\/vdac034","volume":"4","author":"JS Friedman","year":"2022","unstructured":"Friedman JS, Hertz CAJ, Karajannis MA, Miller AM (2022) Tapping into the genome: the role of CSF ctdna liquid biopsy in glioma. Neuro-Oncol Adv 4(Supplement2):ii33\u201340","journal-title":"Neuro-Oncol Adv"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-025-05329-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-025-05329-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-025-05329-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T13:51:08Z","timestamp":1781617868000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-025-05329-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,24]]},"references-count":64,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["5329"],"URL":"https:\/\/doi.org\/10.1007\/s11060-025-05329-x","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,24]]},"assertion":[{"value":"15 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"95"}}